U.S., Jan. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07339059) titled 'SG and Immunotherapy as Maintenance Therapy for Extensive-stage Small-cell Lung Cancer' on Oct. 17, 2025.
Brief Summary: The goal of this clinical trial is to learn if the combination of sacituzumab govetican (SG) and atezolizumab/durvalumab is effective in controlling cancer tumor growth in adults with extensive stage small cell lung cancer. These drugs are FDA approved individually in different cancers. This combination is evaluated in breast cancer and showed promising combination.
The effectiveness of this treatment combination will be measured by changes in tumor size and appearance of new tumors.
Participants in the trial wi...